The UAMS Cancer Institute is home to Arkansas’ only adult Stem Cell Transplantation and Cellular Therapy Program program and is the first and only hospital in Arkansas approved to provide CAR T-cell therapy, a revolutionary new therapy for certain types of non-Hodgkin lymphoma. Learn more.
The Stem Cell Transplantation and Cellular Therapy Program is FACT accredited and meets the most rigorous standards in every aspect of stem cell therapy, from clinical care and donor management to cell collection, processing, storage, transportation, administration and cell release.
The 30-year-old program also is recognized as an Optum Transplant Center of Excellence.
Allogeneic transplants involve the transplantation of stem cells obtained from a donor and are used to treat patients with lymphomas, leukemias and other blood disorders.
Autologous transplants involve the collection of stem cells from a patient’s own bone marrow or blood to be infused into the patient. This type of transplant is used to treat patients with multiple myeloma, relapsed lymphoma and other blood disorders. Learn More
CAR T-cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy uses new technology to genetically modify a patient’s own T cells, enabling them to seek and destroy cancer cells. T cells are a type of white blood cell integral to the immune system. UAMS is authorized to provide CAR T-cell therapy for patients with certain types of non-Hodgkin lymphoma for whom two other rounds of treatment have failed. Learn More
Interested in possibly becoming a stem cell donor? Visit Bethematch.org.